![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Osi Pharmaceuticals Inc. (MM) | NASDAQ:OSIP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 57.49 | 0 | 01:00:00 |
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Expires: February 28, 2011 Estimated average burden hours per response... 0.5 |
|
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940 |
|
1. Name and Address of Reporting Person
*
GRANNER DARYL K |
2. Issuer Name
and
Ticker or Trading Symbol
OSI PHARMACEUTICALS INC [ OSIP ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__ X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
C/O OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
MELVILLE, NY 11747 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 8/1/2008 | M (1) | 1250 | A | $36.125 | 17787 | D | |||
Common Stock | 8/1/2008 | M (1) | 2500 | A | $20.313 | 20287 | D | |||
Common Stock | 8/1/2008 | S (1) | 3750 | D | $52.27 | 16537 | D |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Stock Option (Right to Buy) | $36.125 | 8/1/2008 | M (1) | 1250 | 3/15/2002 (2) | 3/15/2011 | Common Stock | 1250 | $0 | 8750 | D (3) | ||||
Stock Option (Right to Buy) | $20.313 | 8/1/2008 | M (1) | 2500 | 3/15/2001 (2) | 3/15/2010 | Common Stock | 2500 | $0 | 7500 | D (3) |
Explanation of Responses: | |
( 1) | Transaction made pursuant to a 10b5-1 plan dated March 3, 2008. |
( 2) | One third of the stock option became exercisable one year after the date of the grant and the remainder vested ratably on a monthly basis over the succeeding 24 months. |
( 3) | Includes only options with the same termination date. |
Remarks:
On August 5, 2008, the Company filed a Form 4 which incorrectly stated that the Reporting Person exercised options to acquire 3,750 shares at an exercise price of $20.313. In actuality, on August 1, 2008, the Reporting Person exercised options to acquire 2,500 shares at an exercise price of $20.313 and options to acquire 1,250 shares at an exercise price of $36.125. This error was reflected in Form 4s filed for the Reporting Person on September 4, 2008 and October 2, 2008 to report additional exercises from these option grants. As of August 1, 2008, the Reporting Person held 7,500 stock options with an exercise price of $20.313 and 8,750 stock options with an exercise price of $36.125. Exhibit List Exhibit 24--Power of Attorney |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
GRANNER DARYL K
C/O OSI PHARMACEUTICALS, INC. 41 PINELAWN ROAD MELVILLE, NY 11747 |
X |
|
|
|
Signatures
|
||
/s/ Pierre Legault, attorney-in-fact for Dr. Granner | 2/5/2009 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Osi Pharmaceuticals Chart |
1 Month Osi Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions